Glucagon Modulation of Ghrelin Secretion

The Mechanisms Underlying the Glucagon-Induced Suppression of Ghrelin Secretion

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00929812

Enrollment

Registered

2009-06-30

Start date

2006-06-30

Completion date

2009-12-31

Last updated

2009-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 1, Healthy Subjects, Obesity

Keywords

obesity, food intake, glucagon, ghrelin, glucose, insulin

Brief summary

As a counterregulatory hormone for insulin, glucagon plays a critical role in maintaining glucose homeostasis in vivo. It is well known that intramuscular glucagon administration stimulates growth hormone (GH), adrenocorticotropic hormone (ACTH) and cortisol release in humans. Recently, it has been shown that glucagon induces a remarkable decrease in ghrelin levels. The mechanisms underlying this effect are unclear and the role of changes in glucose, insulin, glucagon-like peptide-1 (GLP-1) and catecholamines are widely discussed. The aim of the present study is to further evaluate the effect of glucagon on ghrelin secretion and the possible role of the above mentioned factors in mediating this effect.

Interventions

DRUGGlucagon hydrochloride (GlucaGen®)

1 mg/1 ml of glucagon hydrochloride intramuscularly

DRUGNaCl 0.9%

1 ml NaCl 0.9% intramuscularly

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Subjects \> 18 and \< 60 years old. * Patients with diabetes type 1 should fulfill the following criteria: * ICT Insulin therapy was necessary within the first 3 months after diagnosis; * HbA1c-Wert \< 7%.

Exclusion criteria

* Diabetes type 1 or 2 (for the healthy group). * Biochemical evidence of impaired hepatic or renal function. * History of cardiovascular disease. * Uncontrolled hypertension. * Current inflammatory, malignant or psychiatric disease. * Pregnancy

Design outcomes

Primary

Measure	Time frame
Changes in satiety scale, total and acylated ghrelin concentrations.	During 240 min after Glucagon/Placebo administration.

Secondary

Measure	Time frame
Changes in glucose, insulin and NEFA concentrations.	During 240 min after Glucagon/Placebo administration.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026